Drug delivery systems with modified release for systemic and biophase bioavailability

Current Clinical Pharmacology

Volumn 7, Issue 4, 2012, Pages 282-317

  Leucuta, Sorin E ^a  

^a IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Drug delivery systems; Medicine; Modified release; Pharmacy

Indexed keywords

ADSORBENT; BIOPOLYMER; BUSERELIN; CHLORPHENIRAMINE POLISTIREX PLUS HYDROCODONE POLISTIREX; DOXAZOSIN; ENZYME; ETHYLENE VINYL ACETATE COPOLYMER; FLUGESTONE ACETATE; FLUOROURACIL; GLIPIZIDE; GONADORELIN DERIVATIVE; GOSERELIN; HEPARIN; INDOMETACIN; INSULIN; ION EXCHANGE RESIN; LIGAND; MORPHINE; NANOPARTICLE; NUCLEIC ACID; OROS ACUTRIM; PHENYLPROPANOLAMINE; POLY(ORTHO ESTER); POLYANHYDRIDE; POLYMER; PRAZOSIN; PROCADIA XL; PROTEIN; SILASTIC; SURFACTANT; SYNCHRO MATE C; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL;

ACTIVE TRANSPORT; CANCER PAIN; CELL NUCLEUS; COLLOID; COLON; CONTROLLED DRUG RELEASE; DELAYED DRUG RELEASE; DIABETES MELLITUS; DIFFUSION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DISTRIBUTION; DRUG DOSAGE FORM; DRUG EFFICACY; DRUG EXCRETION; DRUG FORMULATION; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG RELEASE; DRUG SAFETY; DRUG SOLUBILITY; DRUG TARGETING; DRUG TRANSPORT; ENDOCYTOSIS; FEEDBACK SYSTEM; GENE THERAPY; HUMAN; HYDRATION; HYDRODYNAMICS; IMPLANT; IONTOPHORESIS; MAGNETISM; MATHEMATICAL MODEL; MAXIMUM PLASMA CONCENTRATION; METERED DOSE INHALER; MICROEMULSION; MODIFIED DRUG RELEASE; MOLECULAR WEIGHT; MUCOADHESION; NANOPHARMACEUTICS; OSMOSIS; OSMOTIC PRESSURE; OSMOTIC PUMP; PARTICLE SIZE; PASSIVE TRANSPORT; PH; POWDER; PRIORITY JOURNAL; PROSTATE CARCINOMA; PULSATILE DRUG RELEASE; REVIEW; SLOW DRUG RELEASE; SUSPENSION; SUSTAINED DRUG RELEASE; TABLET FORMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSDERMAL PATCH; ULTRASOUND; VAPOR PRESSURE;

EID: 84867756855     PISSN: 15748847     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488412803305786     Document Type: Review

References (396)

1. U.S. Pharmacopeia National Formulary 2011; USP 34 NF 29.
2. European Pharmacopoeia 2010; 7th Edition.
3. Qiu Y. Rational design of oral modified release drug delivery systems. In: Developing solid oral dosage forms, Qiu Y, Chen Y, Zhang GGZ, Eds., Elsevier Inc. 2009; chapter 20.
4. Amidon GL, Lennernäs H, Shah VP, Crison JR. Theoretical basis for a biopharmaceutical drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995; 12: 413-20.
5. Lordi NG. Sustaineed release dosage forms. In: The theory and practice of industrial pharmacy, Lachman L, Lieberman HA, Kanig JL Eds. 3rd Edition. Lea & Febiger, Philadelphia, 1986; chapter 14: pp 431-478.
6. Longer MA, Robinson JR. Sustained release drug delivery system. In: Remington's pharmaceutical sciences, 18th edition. Mack Publishing Company, 1990; Chapter 91: pp 1675-84.
7. Li VH. Influence of drug properties and routes of drug administration on the design of sustained and controlled release systems. In: Controlled drug delivery: fundamentals and applications, Robinson JR, Vincent Lee, Eds. 2nd edition, Marcel Dekker, Inc., 1978; 29: Chapter 1: pp 5-36.
8. Hoffman AS. The origins and evolution of "controlled" drug delivery systems. J Controlled Release 2008; 132: 153-163.
9. George M, Grass IV, Robinson J. Sustained and controlled release drug delivery systems. In: Modern Pharmaceutics, Banker GS., Rhodes CT, Eds. Marcel Dekker, 1990; 2nd edition. Chapter 6: pp. 639-58.
10. Hui Ho-Wah. Design and fabrication of oral controlled release drug delivery systems. In: Controlled drug delivery; fundamentals and applications, Robinson JR, Vincent L., Eds. Marcel Dekker Inc., 2nd edition, Volume 29, 1978; Chapter 9: pp 391-420.
11. Wen H, Park K. Oral controlled release formulation design and drug delivery: theory and practice, John Wiley & Sons, Inc.: 2010.
12. Li X, Jasti BR. Design of controlled release drug delivery systems. McGraw-Hill: 2006.
13. Rathbone MJ, Hadgraft J, Roberts MS. Modified-release drug delivery technology. Marcel Dekker, Inc.: New York-Basel 2003.
14. Leucuta SE. Medicines with modifyed release (in Romanian). Editura Casa Cartii de Stiinta: Cluj-Napoca 2011; 383pp.
15. Kayser O, Lemke A, Hernandez-Trejo N. The impact of nanobiotechnology on the development of new drug delivery systems. Curr Pharm Biotechnol 2005; 6: 3-5.
16. Pathak Y, Thassu D. Drug delivery nanoparticles. Formulation and characterization. Series: Drugs and pharmaceutical sciences, 2nd edition, Informa: 2009.
17. Prokop A, Davidson JM. Nanovehicular intracellular delivery systems. J Pharm Sci 2008; 97: 3518-90.
18. Leucuta SE. Nanotechnology for delivery of drugs and biomedical applications. Curr Clin Pharmacol 2010; 5: 257-80.
19. Guidance for Industry Bioavailability and Bioequivalence Studies for Orally Administered Drug Products-General Considerations. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) March 2003. http: //www.fda.gov/cder/guidance/index.htm.
20. Joung YK, Son S, Jang JY, Kwon MH, Park KD. Sustained cytoplasmic delivery and anti-viral effect of plga nanoparticles carrying a nucleic acid-hydrolyzing monoclonal antibody. Pharm Res 2012; 29: 932-42.
21. Derendorf H, Meibohm B. Modeling of pharmacokinetic/ pharmacodynamic (PK/PD) relationships: concepts and perspectives. Pharm Res 1999; 16: 176-85.
22. Gibaldi M, Perrier D. Pharmacokinetics. M Dekker, Inc.: New York 1975.
23. Rowland M, Tozer N. Clinical pharmacokinetics. Concepts and applications. Lea & Febiger: Philadelphia 1980.
24. Evans WE, Schentag JJ, Jusko WJ. Applied pharmacokinetics. Principles of therapeutic drug monitoring. Applied Therapeutics Inc.: San Francisco 1980.
25. Kendall MJ, John VA. The role of clinical pharmacology in the development and evaluation of oral controlled-release dosage forms. Br J Clin Pharmac 1985; 19: 65S-67S.
26. Gabrielson J, Green AR. Quantitative pharmacology or pharmacokinetic pharmacodynamic integration should be a vital component in integrative pharmacology. J Pharmacol ExperimTherap 2009; 33: 767-74.
27. Chen ML, Shah VP, Crommelin DJ, et al. Harmonization of regulatory approaches for evaluating therapeutic equivalence and interchangeability of multisource drug products: Workshop Summary Report. AAPS J 2011; 13: 556-64.
28. Weinshilboum RM, Wang L. Pharmacogenetics and Pharmacogenomics: Development, Science, and Translation. Ann Rev Genomics Human Genet 2006; 7: 223-45.
29. Harrison N. Conference Scene: Report on the pharmacogenomics and personalized medicine. Pharmacogenomics 2012; Conference: Part 1, 13: 141-5; Part 2, 13: 265-8.
30. Uchizono JA. Application of pharmacokinetics and pharmacodynamics in the design of controlled delivery systems, In: Li X, Jasti BR. Eds. Design of controlled release drug delivery systems: McGraw Hill 2006; Chapter 1.
31. Leucuta SE. Biopharmacy and Pharmacokinetics (in Romanian), Editura Dacia: Cluj-Napoca 2002; 297 pp.
32. Leucuta SE, Vlase L. Pharmacokinetics and metabolic drug interactions. Curr Clin Pharmacol 2006; 1: 5-20.
33. Wilson CG, Washington N. Physiological pharmaceutics. Biological barriers to drug absorption. Ellis Horwood LTD.: New York 1990.
34. Wells JI. Pharmaceutical preformulation. The physico-chemical properties of drug substances. Ellis Horwood Ltd.: 1987.
35. Wells JI, Aulton E. Pharmaceutical preformulation. In: Aulton M E, Ed. Aulton's Pharmaceutics: The Design and Maufacture of Medicines, 3rd ed, Churchill Livingstone, Elsevier, 2002; pp 336-60.
36. Martin A, Swarbrick J, Cammarata A. Physical Pharmacy, 3rd edition, Lea & Febiger: Philadelphia 1983.
37. Amidon GL, Lennernäs H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995; 12: 413-20.
38. Benet LZ, Broccatelli F, Oprea TI. BDDCS applied to over 900 drugs. AAPS J 2012; 13: 519-47.
39. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry: Waiver of in vivo bioavailability and bioequivalence studies for immediate release solid oral dosage forms based on a BCS. 2000 August.
40. Committee for Medicinal Products for Human Use, European Medicines Agency. Guideline on the investigation of bioequivalence, 2010 January 20.
41. Rowe RC, Sheskey PJ, Quinn ME. Handbook of Pharmaceutical excipients, 6th Edition, APhA, Pharm. Press: London, Chicago 2009.
42. Wehrle P, Nobelis P, Stamm A. Principales methods d'optimisation employees en genie pharmaceutique. I. Les methodes exploratoires, S.T.P. Pharma, 1989; 5: 481-9.
43. Armstrong NA. Pharmaceutical experimental design and interpretation. Taylor-Francis: London 2006.
44. Lewis GA, Mathieu D, Phan-Taan-Luu R. Pharmaceutical experimental design. M. Dekker: New-York 1999.
45. Schwartz JB. Optimization techniques in pharmaceutical formulation and processing. In: Modern Pharmaceutrics, Banker GS, Rhodes CT, Eds. M. Dekker Inc.: New-York 1979; Chap.17.
46. Ozil P, Caire JP. Initiation aux plans d'expériences. Centre de recherche en électrochimie minérale et en génie des procèdes: Grenoble 1995.
47. Goupy J. La méthode des plans d'expériences. Bordas: Paris 1988.
48. Leucuta SE, Tomuta I. Experimental plans for the optimization of the preparation of medicines (Romanian). Editura Roprint: Cluj-Napoca 2011.
49. Hwang R, Kowalski DL. Design of experiments for formulation development. Pharm Technol 2005.
50. Bolton S. Statistical applications in the pharmaceutical sciences. In: The Theory and Practice of Industrial Pharmacy, Lachman L, Lieberman HA, Kanig J, Eds., 3rd ed., Lea-Febiger: Philadeplphia 1986, Chap. 10.
51. Tinsson W. Plans d'expérience: constructions et analyses statistiques. Springer, 2010.
52. Martin A. Physical Pharmacy, 4th ed., Lea & Febiger: Philadelphia 1993.
53. Banakar UV. Pharmaceutical dissolution testing. M. Dekker Inc.: New York 1992.
54. Buri P, Puisieux F, Doelker E, Benoit JP. Formes pharmaceutiques nouvelles. Tec. Doc. Lavoisier: Paris. 1985.
55. Kydonieus A. Treatise on controlled drug delivery. M. Dekker Inc.: New York 1992.
56. Baker RW, Lonsdale HK. Controlled release: mechanisms and rates. In: Controlled release of biologically active agents, Tanquary AC, Lacey RE, Eds. Plenum Press: New York 1974.
57. Chien YW. Novel drug delivery systems, 2nd ed., M. Dekker Inc.: New York 1992.
58. Peppas NA. Mathematical modeling of diffusion processess in drug delivery polymeric systems. In: Controlled drug bioavailability, vol.1, Smolen VF, Ball LA, Eds. Wiley: New York 1983.
59. Hillery AM. Drug delivery: The basic concepts. In: Hillery A M, Lloyd A W, Swarbrick J., Eds. Drug delivery and targeting for pharmacists and pharmaceutical scientists. Taylor and Francis: London, 2001.
60. Gostoli C, Sarti GC. Diffusion and localized swelling resistances in glassy polymers. Polymer Eng Science1982; 22: 1018-26.
61. Colombo P, Bettini R., Peppas NA. Observation of swelling process and diffusion front position during swelling in hydroxypropylmethylcellulose (HPMC) matrices containing a soluble drug. J Control Release 1999; 61: 83-91.
62. Conte U, Colombo P, Gazzaniga A, Sangalli ME, La Manna A. Swelling-activated drug delivery systems. Biomaterials 1988; 9: 489-493.
63. Peppas NA, Ségot-Chick S. Les dispositifs à libération contrôlée pour la délivrance des principes actifs médicamenteux. II. Aspects fondamentaux de la diffusion des principes actifs dans les polymères. STP Pharma 1985; 1: 121-7.
64. Peppas NA, Ségot-Chick S. Les dispositifs à libération contrôlée pour la délivrance des principes actifs médicamenteux. III. Modélisaton des mécanismes diffusionnels. STP Pharma 1985; 1: 208-16.
65. Siepmann J, Siegel R A, Rathbone MJ. Fundamentals and applications of controlled release drug delivery. Springer 2012.
66. Langer RS, Peppas NA. Chemical and physical structure of polymers as carriers for controlled release of bioactive agents: a review, JMS-REV. Macromol Chem Phys C23 1983; 1: 61-126.
67. Hopfenberg HB. Controlled release from erodible slabs, cylinders and spheres, Controlled release polymeric formulations In: Paul DR, Harris FW., Eds. American Chemical Society: Washington 1976.
68. Heller J, Baker RW, Gale R M, Rodin JO. Controlled drug release by polymer dissolution.I. Partial esters of maleic anhydride copolymers-properties and theory, J Appl Polym Sci 1978; 22: 1991-2009.
69. Gander B, Gurny R, Doelker E. Marices à libération contrôlée par le gonflement du polymère.I. Mécanisms de penétration des solvants dans les polymères. Pharm Acta Helv 1986; 61: 130-4.
70. Gander B, Gurny R, Doelker E. Marices à libération contrôlée par le gonflement du polymère. II. Préparation des systèmes médicamenteux et analyse de la cinétique de libération, Pharm Acta Helv 1986; 61: 178-84.
71. Chien YW. New developments în drug delivery. Med Res Rev 1990; 10: 476-504.
72. Chien YW. Novel Drug Delivery Systems, 2nd ed., M. Dekker Inc.: New York 1992.
73. Guy RH. Current status and future prospects of transdermal drug delivery, Pharm Res 1996; 13: 1765-9.
74. Acoul KL, Pavan-Langston D. Pilocarpine ocusert system for sustained control of ocular hypertension. Arch Ophthalmol 1975; 93: 587-90.
75. http: //www.drugs.com/ Nitro-Dur patch.
76. Rathbone MJ, Macmillan K L, Inskeep K, et al. Fertility regulation in cattle. J Contr Release 1998; 54: 117-48.
77. Chien YW, Lin S. Optimisation of treatment by applying programmable rate-controlled drug delivery technology. Clin Pharmacokinet 2002; 41 (15): 1267-99.
78. Ghosh T, Ghosh A. Drug delivery through osmotic systems-an overview. J Applied Pharm Sci 2011; 1: 38-49.
79. Gupta BP, Thakur N, Jain NP, Banweer J, Jain S. Osmotically controlled drug delivery system with associated drugs. J Pharm Pharmaceut Sci 2010; 13: (3) 571-588.
80. Theeuwes F. Elementary osmotic pump. J Pharm Sci 1975; 64: 1987-91.
81. Ueda H, Sugibayashi K, Morimoto Z. Skin penetration enhancing effects of drugs by phonophoresis. J Control Release 1995; 37: 291-7.
82. www.perimed-instruments.com/brochures/Iontophoresis_Perimed. pdf.
83. www.slideshare.net/./parenteral-controlled-drug-delivery-system.
84. Balamuralidhara V, Pramodkumar TM. pH sensitive drug delivery systems. Amer J Drug Discov Dev 2011; 1: 24-48.
85. www.docstoc.com/docs/69298975/Concept-and-System-Designfor-Rate-Controlled.
86. Garnier P, Wang XT, Robinson MA, et al. Lectin-directed enzyme activated prodrug therapy (LEAPT): synthesis and evaluation of rhamnose-capped prodrugs. J Drug Targeting 2010; 18(10): 794-802.
87. Robinson JR, Lee VHL. Controlled Drug Delivery: Fundamentals and Applications, Drugs and the Pharmaceutical Sciences; v. 29, 2nd ed. Revised and Expanded, Marcel Dekker,1987.
88. Lordi NJ. Sustained release dosage forms. In: Lachman L, Lieberman H A, Kanig J L, Eds. The Theory and Practice of Industrial Pharmacy, 3d ed., Lea & Febiger: Philadelphia 1986, pp. 430-478.
89. Banakar UV. Pharmaceutical dissolution testing, M. Dekker Inc.: New York 1992.
90. Noyes A, Whitney W. The rate of solution of solid substances in their own solutions. J Am Chem Soc 1897; 19: 930-4.
91. Crank J. The mathematics of diffusion. Clarendon Press: Oxford 1975.
92. Dash S, Murthy P N, Nath L, Chowdhury P. Kinetic modeling on drug release from controlled drug delivery systems. Acta Poloniae Pharmaceutica Drug Res 2010; 67: 217-23.
93. Singhvi G, Singh M. Review: In-Vitro drug release characterization models. Int J Pharm Stud Res 2011; 2: 77-84.
94. Arifin DY, Lee LY, Wang CH. Mathematical modeling and simulation of drug release from microspheres: Implications to drug delivery systems. Adv Drug Deliv Rev 2006; 58: 1274-325.
95. www.authorstream.com/Presentation/aSGuest106867-1122372-dissolution.
96. Narashimhan B, Mallapragada SK, Peppas NA. Release kinetics, data interpretation. In: Mathiowitz E., Ed., Encyclopedia of Controlled Drug Delivery, John Wiley and Sons, Inc.: New York 1999.
97. Hixson AW, Crowell JH. Dependence of reaction velocity upon surface and agitation (I) theoretical consideration. Ind Eng Chem 1931; 23: 923-31.
98. Chen S, Zhu J, Cheng J. Preparation and in vitro evaluation of a novel combined multiparticulate delayed-onset sustained-release formulation of diltiazem hydrochloride. Pharmazie 2007; 62: 907-13.
99. Higuchi T. Rate of release of medicaments from ointment bases containing drugs in suspension. J Pharm Sci 1961; 50: 874-5.
100. Higuchi T. Mechanism of sustained-action medication. Theoretical analysis of rate of release of solid drugs in solid matrices. J Pharm Sci 1963; 52: 1145-9.
101. Korsmeyer R, Gurny R, Doelker E, Buri P, Peppas NA. Mechanism of solute release from porous hydrophilic polymers. Int J Pharm 1983; 15: pp 25-35.
102. Ritger P, Peppas NA. Simple equation for description of solute release: II. Fickian and anomalous release from swellable devices. J Contr Rel 1985; 5: 37-42.
103. Siepmann J, Peppas NA. Adv Drug Deliv Rev 2001; 48: 139-57.
104. Singh J, Gupta S, Kaur H. Prediction of in vitro drug release mechanisms from extended release matrix tablets using ssr/r2 technique. Trends Appl Sci Res 2011; 6: 400-9.
105. Baker RW, Lonsdale HS. In: Controlled release of biologically active agents, Tanquary AC, Lacey RE., Eds., Plenum Press: New York 1974.
106. Costa P, Lobo Sousa JM. Modeling and comparison of dissolution profiles. Eur J Pharm Biofarm 2001; 13: 123-33.
107. Hopfenberg HB. In: Controlled Release Polymeric Formulations, Paul DR, Haris FW, Eds., ACS Symposium Series No. 33, American Chemical Society: Washington 1976.
108. Moore J W, Flanner H H. Mathematical comparison of curves with an emphasis on in vitro dissolution profiles. Pharm Tech 1996; 20: 64-74.
109. Shah VP, Tsong Y, Sathe P. In vitro dissolution profile comparison
110. Gohel MC, Sarvaiya KG, Mehta NR, et al. Assessment of similarity factor using different weighting approaches. Dissolution Technologies, Nov. 2005; 22-27.
111. Costa P. An alternative method to the evaluation of similarity factor in dissolution testing. Int J Pharm 2001; 220: 77-83.
112. Bermejo M. Dissolution methodologies and IVIVC. ODD Lake Tahoe, March 2002.
113. Food and Drug Administration, CDER, August 1997, Guidance for industry. Dissolution testing of immediate release solid oral dosage forms.
114. Pena D, Galeano P. A unified approach to model selection, discrimination, goodness of fit and outliers in time series. Stat Industry Technol 2008; 7: 267-78.
115. Zhang Y, Huo M, Zhou J, et al. DDSolver: an Add-In program for modeling and comparison of drug dissolution profiles. AAPS J 2010; 12: 263-71.
116. Akaike H. A new look at the statistical model identification. IEEE Transactions Automatic Control 1974; 19: 716-23.
117. Ranade VV. Drug delivery systems 5A. Oral drug delivery. J Clin Pharmacol 1991; 31: 2-16.
118. Verma RK, Krishna DM, Garg S. Formulation aspects in the development of osmotically controlled oral drug delivery systems. J Contr Release 2002; 79: 7-27.
119. Akala EO. In: Theory and Practice of Contemporary Pharmaceutics, Jasti BR, Ghosh TK., Eds, CRC Press 2004; chapter 11.
120. Staniforth JN, Baichwal AR. Synergistically interacting heterodisperse polysaccharides: function in achieving controllable drug delivery. In: El-Nokaly MA, Piatt DM, Charpentier BA, Eds. Polymeric Delivery Systems: Properties and Applications. Amer Chem Soc 1993; pp. 327-50.
121. Baichwal R, Staniforth J N. Directly compressible sustained release excipient. US patent 4, 994, 276, 1991.
122. Altaf SA, Yu KL, Parasrampuria J, Friend DR. Guar gum-based sustained release diltiazem. Pharm Res 1998; 15: 1196-201.
123. Chopra SK, Nangia AK, Lee D, Molloy T. Controlled release device. European patent 0,542,364 A1, 1993.
124. Cremer K, Asmussen B. Novel controlled release tablet with erodible layers. Proc Int Symp Control Rel Bioact Mater 1995; 22: 732-33.
125. Conte U, Maggi L. Modulation of the dissolution profiles from Geomatrix multilayer tablets containing drugs of different solubility. Biomaterials 1996; 17: 889-96.
126. Kerc J, Mohar M, Kofler B. Three-phase pharmaceutical form (Threeform) for nifedipine zero order release. Proc Int Symp Control Rel Bioact Mater 1998; 25: 912-3.
127. Liversidge GG, Cundy K C. Particle size reduction for improvement of oral bioavailability of hydrophobic drugs. I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs. Int J Pharm 1995; 125: 91-7.
128. Haynes DH. Phospholipid-coated microcrystals: injectable formulations of water insoluble drugs. US patents 5,091,187 and 5,091,188, 1992.
129. Mishra A, Robinson G, Pace G. Novel injectable formulations of water-insoluble drugs. Contr Release Newslett 2000; 17: pp 21-30.
130. Bodea A, Leucua SE. Optimization of hydrophilic matrix tablets using a D-optimal design. Int J Pharm 1997; 153: pp 247-55.
131. Bodea A, Leucua SE. Optimization of propranolol hydrochloride sustained release pellets using a factorial design. Int J Pharm 1997; 154: pp 49-57.
132. Bodea A, Leucua SE. Optimization of propranolol hydrochloride sustained-release pellets using Box-Behnken design and desirability function. Drug Dev Ind Pharm 1998; 24: 145-55.
133. Iovanov IR, Tomuta I, Leucuta SE. Influence of some formulation factors on the release of felodipine from extended release hydrophilic matrix tablets. Farmacia 2009; 57: 590-7.
134. Verma RK, Arora S, Garg S. Osmotic pumps in drug delivery. Crit Rev Ther Drug Carrier Syst 2004; 21(6): 477-520.
135. Wen H, Park K. Oral controlled release formulation design and drug delivery. Wiley, 2010.
136. Gupta S, Singh R P, Sharma R, et al. Osmotic pumps: a review. Pharmacie globale 2011; 2: 1-8.
137. www.alzet.com.
138. Moes AJ. Gastroretentive dosage forms. Crit Rev Ther Drug Carrier Syst 1993; 10: 143-95.
139. Katakam VK, Somagoni JM, Reddy S, Eaga CM, Rallabandi BRC, Yamsani MR. Floating drug delivery systems: a review. Curr Trend Biotechnol Pharm 2010; 4: 610-47.
140. Garg R, Gupta GD. Progress in controlled gastroretentive delivery systems. Trop J Pharm Res 2008; 7: 1055-66.
141. Hoffman A, Stepensky D, Lavy E, Eyal S, Klausner E, Friedman M. Pharmacokinetic and pharmacodynamic aspects of gastroretentive dosage forms. Int J Pharm 2004; 277: 141-53.
142. Jimenez Castellanos MR, Zia H, Rhodes CT. Design and testing in vitro of a bioadhesive and floating drug delivery system for oral application. Int J Pharm 1994; 25: 65-70.
143. Chawla G, Gupta P, Koradia V, Bansal AK. Gastro retention: a means to address regional variability in intestinal drug absorption. Pharm Tech 2003; 50-68.
144. Rouge N, Buri P, Doelker E. Drug absorption site in gastrointestinal tract and dosage forms for site specific delivery. Int J Pharm 1996; 136: 117-39.
145. Hirtz J. The GIT absorption of drugs in man: a review of current concepts and methods of investigation. Br J Clin Pharmacol 1985; 19: 77S-83S.
146. Ponchel G, Irache JM. Specific and non-specific bioadhesive particulate system for oral delivery to the gastrointestinal tract. Adv Drug Del Rev 1998; 34: 191-219.
147. Lenaerts VM, Gurny R. Gastrointestinal tract-physiological variables affecting the performance of oral sustained release dosage forms. In: Lenaerts V, Gurny R, Eds. Bioadhesive Drug Deliv Syst CRC Press: Boca Raton 1990.
148. Deshpande AA, Shah NH, Rhodes CT, Malick W. Development of a novel controlled-release system for gastric retention. Pharm Res 1997; 14: pp 815-9.
149. Leucuta SE, Follidis M, Capalneanu R, Mocan A. Relative bioavailability of different oral sustained release oxprenolol tablets. Eur J Drug Metab Pharmacokin 1998; 23: 178-84.
150. Shah SH, Patel JK, Patel NV. Stomach specific floating drug delivery system: a review. Intl J PharmTech Res 2009; 1: 623-633.
151. Singh BM, Kim KH. Floating drug delivery systems: an approach to controlled drug delivery via gastric retention. J Control Release 2000; 63: 235-59.
152. Strusi OL, Sonvico F, Bettini R, et al. Module assemblage technology for floating systems: in vitro flotation and in vivo gastro-retention. J Contr Release 2008; 129(2): 88-92.
153. Murphy C, Pillay V, Choonara YE, et al. Optimization of a dual mechanism gastrofloatable and gastroadhesive delivery system for narrow absorption window drugs. AAPS Pharm Sci Tech 2012; 13: 1-15.
154. Leucuta SE, Follidis M, Capalneanu R, Mocan A. Relative bioavailability of different oral sustained release oxprenolol tablets. Eur J Drug Metab Pharmacokin 1998; 23: 178-84.
155. Yang L, Chu JS, Fix JA. Colon specific drug delivery: new approaches and in vitro/in vivo evaluation. Int J Pharm 2002; 235: 1-15.
156. Jose S, Dhanya K, Cinu TA, Litty J, Chacko AJ. Colon targeted drug delivery: different approaches. J Young Pharm [serial online] 2009; 1: 13-9.
157. Kinget R, Kalala W, Vervoort L, van den MG. Colonic drug targeting. J Drug Target 1998; 6: 129-49.
158. Tamara M. Drug targeting to the colon with lectins and neoglycoconjugates. Adv Drug Deliv Rev 2004; 56: 491-509.
159. Fell JT. Targeting of drugs and delivery systems to specific sites in the gastrointestinal tract. J Anat 1996; 89: 517-9.
160. Chourasia MK., Jain SK. Pharmaceutical approaches to colon targeted drug delivery systems. J Pharm Pharmaceut Sci 2003; 6: 33-66.
161. Mackay M, Phillips J, Hastewell J. Peptide drug delivery: colonic and rectal absorption. Adv Drug Deliv Rev 1997; 28: 253-73.
162. Yamamoto AZ, Muranishi S. Rectal drug delivery systems. Improvement of rectal peptide absorption by absorption enhancers, protease inhibitors and chemical modification. Adv Drug Deliv Rev 1997; 28: 275-99.
163. Philip AK, Philip B. Colon targeted drug delivery systems: a review on primary and novel approaches. Oman Medical J 2010; 25: 1-9.
164. Fatima L, Asghar A, Chandran S. Multiparticulate formulation approach to colon specific drug delivery: current perspectives, J Pharm Pharmaceut Sci 2006; 9: 327-38.
165. Singh BN. Modified-release solid formulations for colonic delivery, Recent Patents on Drug Delivery & Formulation 2007; 1: 53-63.
166. Haeberlin B, Rubas W, Nolen HW, Friend DR. In vitro evaluation of dexamethasone-b-D-glucuronide for colon-specific drug delivery. Pharm Res 1993; 10: 1553-62.
167. Rajguru VV, Gaikwad PD, Bankar VH, Pawar SP. An overview on colonic drug delivery system. Int J Pharm Sci Rev Res 2011; 6: 197-204.
168. Sinha VR, Kumria R. Microbially triggered drug delivery to the colon. Eur J Pharm Sci 2003; 18: 3-18.
169. Kumar KVV, Sivakumar T, Tamizhmani T. Colon targeting drug delivery system: A review on recent approaches. Int J Pharm Biomed Sci 2011; 2: 11-9.
170. Philip AK, Philip B. Colon targeted drug delivery systems: a review on primary and novel approaches. OMJ 2010; 25: 70-8.
171. Swanson D, Barclay B, Wong P, Theeuwes F. Nifedipine gastrointestinal therapeutics system. Am J Med 1987; 8(6): 3-10.
172. Watanabe S, Kawai H, Katsuma M, Fukui M. Colon specific drug release system. U. S. Patent, 1998; 09/183339.
173. Li J, Yang L, Ferguson SM, et al. In vitro evaluation of dissolution behavior for a colon-specific drug delivery system (Codes™) in multi-pH media using United States Pharmacopeia apparatus II and III. AAPS Pharm SciTech 2002; 3(4): E33 pp.1-9.
174. Tomuta I, Leucuta SE. Preparation and in vitro characterization of colon release pellets with pH and time control mechanism. Farmacia 2006; 54: 51-60.
175. Tomuta I, Leucuta SE. Validation of the laboratory scale technological process preparation of a colonic release pharmaceutical system with pH and time control. Farmacia 2009; 57: 272-81.
176. Tomuta I, Vlase L, Popa A, Leucuta SE. Invitro-in vivo evaluation of a novel drug delivery system for colonic targeting. Farmacia 2010; 58: 368-77.
177. Bussemer T, Otto I, Bodmeier R. Pulsatile drug delivery systems. Crit Rev Ther Drug Carrier Syst 2001; 18(5): 433-58.
178. Shidhae SS, Lotlikar VM, Ghule AM, Phutane PK, Kadam VJ. Pulsatile delivery systems. An approach for chronotherapeutic diseases. Syst Rev Pharm 2010; 1 pp 55-61.
179. Anal AK. Time-controlled pulsatile delivery systems for bioactive compounds. Recent Patents on Drug Delivery & Formulation 2007; 1: 73-9.
180. Gazzaniga A, Palugan L, Foppoli A, Sangalli ME. Oral pulsatile delivery systems based on swellable hydrophilic polymers. Eur J Pharm Biopharm 2008; 68: 11-8.
181. Nayak UY, Shavi GV, Nayak Y, et al. Chronotherapeutic drug delivery for early morning surge in blood pressure: A programmable delivery system. J Contr Release 2009; 136: 125-31.
182. Gothoskar AV, Joshi AM, Joshi NH. Pulsatile drug delivery systems: a review. Drug Deliv Technol 2004; 4: (5) 1-8.
183. Reddy JRK, Jyothsna MV, Saleem TSM, Chetty CMS. Review on: pulsatile drug delivery systems. J Pharm Sci & Res 2009; 1: 109-15.
184. Roy P, Shahiwala A. Multiparticulate formulation approach to pulsatile drug delivery: current perspectives. J Controll Release 2009; 134: 74-80.
185. Arora S, Ali J, Ahuja A, Baboota S, Qureshi J. Pulsatile drug delivery systems: an approach for controlled drug delivery. Indian J Pharm Sci 2006; 68: 295-300.
186. Patel JD, Aneja K, Majumdar SH. Pulsatile drug delivery system: an "user-friendly" dosage form. JPRHC 2010; 2: 204-15.
187. Youan B. Chronopharmaceutics: Gimmick or clinically relevant approach to drug delivery. J Control Release 2004; 98: 337-53.
188. Medlicott NJ, Tucker IG. Pulsatile release from subcutaneous implants Advanced Drug Delivery Rev 1999; 38: 139-49.
189. Parmar RD, Parikh RK, et al. Pulsatile drug delivery systems: an overview. Int J Pharm Sci Nanotechnol 2009; 2: 605-14.
190. Belgamwar V, Gaikwad M, Patil G, Surana S. Pulsatile drug delivery system. Asian J Pharma 2008; 2: 141-.
191. Patrick S, Wong L, Gupta S, Stewart B. Osmotically controlled tablets. In: Rathbone M, Hadgraft J, Roberts M. Modified-release drug delivery technology. Informa Health Care: London 2003; p. 113.
192. Gothoskar AV, Joshi AM, Joshi NH. Pulsatile Drug Delivery Systems: A Review. Drug Dev Deliv 2004; 4: (5) 1-4.
193. Wilding IR, Davis SS, Pozzi F, Furlani P, Gazzaniga A. Enteric coated timed release systems for colonic targeting. Int J Pharm 1994; 111: 99-102.
194. Gazzaniga A, Iamartino P, Maffione G, Sangalli ME. Oral delayedrelease system for colonic specific delivery. Int J Pharm 1994; 2(108): 77-83.
195. Gazzaniga A, Sangalli ME, Giordano F. Oral chronotopic & Mac226: drug delivery systems: achievement of time and/or site specifity. Eur J Biopharm 1994; 40(4): 246-50.
196. Ueda S, Hata T, Yamaguchi H, Kotani M, Ueda Y. Development of a novel drug release system, time controlled explosion system (TES): I: Concept and design. J Drug Target 1994; 2: 35-44.
197. Narisawa S, Nagata M, Hirakawa Y, Kobayashi M, Yoshino H. An organic acid induced sigmoidal release system for oral controlled release preparations: 2, Permeability enhancement of Eudragit RS coating led by the physico-chemical interactions with organic acid. J Pharm Sci 1996, 85: 184-8.
198. Vonica AL, Tomuta I, Leucuta SE. Experimental design for the screening of three types of coating polymers for metoprolol minitablets with pulcatile release. Farmacia 2011, 59: 742-9.
199. Survase S, Kumar N. Pulsatile drug delivery: current scenario. CRIPS 2007; 8: 27-33.
200. Shukla D, Chakraborty S, Singh S, Mishra B. Mouth dissolving tablets I: An overview of formulation technology. Sci Pharm 2009; 76: 309-26.
201. Bhowmik D, Chiranjib B, Krishnakanth P, Chandira RM. Fast dissolving tablet: an overview. J Chem Pharm Res 2009; 1: 163-177.
202. Ratnaparkhi M P, Mohanta G P, Upadhyay L. Review on: fast dissolving tablet. J Pharm Res 2009; 2: 5-12.
203. Gupta A, Mishra AK, Gupta V, Bansal P, Singh R, Singh AK. Recent trends of fast dissolving tablet-an overview of formulation technology. Int J Pharm Biol Arch 2010; 1: 1-10.
204. U.S. Department of Health and Human Services. Food and Drug Administration. Guidance for industry-Orally disintegrating tablets. http: //www.fda.gov/downloads/Drugs/GuidanceCompliance RegulatoryInformation/Guidances/ucm070578.pdf.
205. European Pharmacopoeia 5.0. http: //lib.njutcm.edu.cn/yaodian/ep/ EP5.0/16_monographs/monographs_d-k/index.pdf.
206. Fu Y, Yang S, Jeong S, Kimura S, Park K. Orally fast disintegrating tablets: developments, technologies, taste-masking and clinical studies. Crit Rev TherDrug Carr Syst 2004; 21: 433-75.
207. Saettone M F, Salminen L. Ocular inserts for topical delivery, Adv Drug Deliv Rev 1995; 16: 95-106.
208. LeBourlais C, Acar L, Zia H, Sado PA, Needham T, Leverge R. Ophthalmic drug delivery systems-recent advances. Progress Retinal Eye Res 1998; 17: 33-58.
209. Thakur RR, Kashiv M. Modern delivery systems for ocular drug formulations: a comparative overview W.R.T. conventional dosage forms. Int J Res Pharm Biomed Sci 2o011; 2: 1-10.
210. Short BG. Safety evaluation of ocular drug delivery formulations: techniques and practical considerations. Toxicol Pathol 2008; 36: 49-62.
211. Davis JL, Gilger BC, Robinson MR. Novel approaches to ocular drug delivery. Curr Opin Mol Therap 2004; 6: 195-205.
212. Graves JL, Olejnik O, Wilson CG. Polymers and the precorneal tear film. A.T. P Pharma Sci 1992; 2: 13-33.
213. Mali MN, Hajare AA. In situ gel-forming systems for sustained ocular drug delivery. European Industrial Pharmacy 2010; Issue 5: 17-20.
214. Bourges JL, Gautier SE, Delie F, et al. Ocular drug delivery targeting the retina and retinal pigment epithelium using polylactide nanoparticles. Invest Opth Vis Sci 2003; 44: 3562-9.
215. Leucuta SE. The kinetics of in vitro release and pharmacokinetics of miotic response in rabbits of gelatin and albumin mpcrospheres with pilocarpine. Int J Pharm 1988; 41: 213-7.
216. Lee VHL. Ocular drug delivery of progesterone using nanoparticles. J Micoencapsul 1986; 3: 213-8.
217. Irache JM. Albumin nanoparticles for the intravitreal delivery of anticytomegaloviral drugs. Mini Rev Med Chem 2005; 5: 293-305.
218. Middleton DL, Leung SHS, Robinson JR. In: Lenaerts V, Gurny R. Eds., Bioadhesive Drug Delivery Systems, CRC Press, Boca Raton 1990.
219. Meisner D, Mezei M. Liposome ocular delivery systems. Adv Drug Deliv Rev 1995; 16: 75-93.
220. Kumari A, Sharma PK, Garg VK. Ocular inserts. Advancement in therapy or eye diseases. J Advance Pharm Technol Res 2010; 3: 87-96.
221. Saettone MF. Solid polymeric inserts/disks as drug delivery devices. In: Edman P., Ed. Biopharmaceutics of ocular drug delivery. Boca Raton, CRC Press, 1993, 61-79.
222. Maichuk YF. Ophthalmic drug inserts. Invest Ophthalmol 1975; 14: 87-90.
223. Bayens V, Kaltsatos V, Boisrame B, Fathi M, Gurny R. Evaluation of soluble bioadhesive ophthalmic drug inserts (BODI) for prolonged release of gentamicin: lachrymal pharmacokinetics and ocular tolerance. J Ocul Pharmacol Ther 1998; 14: 263-72.
224. Lee YC, Millard JW, Negvesky GJ, Butrus SI, Yalkowsky SH. Formulation and in vivo evaluation of ocular inserts containing phenylephrine and tropicamide. Int J Pharm 1999; 182: 121-6.
225. Urquhart J. Development of the Ocusert pilocarpine ocular therapeutic systems: A case history in ophthalmic product development. In: Robinson J R, Ed., Ophthalmic drug delivery systems, American Pharmaceutical Association: Washington 1980; 105-116.
226. http: //www.orgyn.com/resources/genrx/D003122.asp.
227. Yasukawa T, Ogura Y, Kimura H, Sakurai E, Tabata Y. Drug delivery from ocular implants. Expert Opin Drug Deliv 2006; 3: 261-73.
228. Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol 2008; 26: 1261-8.
229. Guy RH, Hadgraft J. Transdermal drug delivery, Marcel Dekker, Inc.: New York 2003.
230. Chandrashekar NS, Shobha Rani RH. Physicochemical and pharmacokinetic parameters in drug selection and loading for transdermal drug delivery. Indian J Pharm Sci 2008; 70: 94-6.
231. Patel RP, Baria AH. Formulation and evaluation considerations of transdermal drug delivery system. Int J Pharm Res 2011; 3(1): 1-9.
232. Flynn GL. Topical drug absorption and topical pharmaceutical systems. In: Modern Pharmaceutics. Banker GS, Rhodes CT, Eds., M. Dekker Inc: New York 1979; Chap.8.
233. Smith EW, Maibach HI. Percutaneous penetration enhancers. CRC Press, Boca Raton 1995.
234. Tiwary AK, Sapra B, Jain S. Innovations in transdermal drug delivery: formulations and techniques. Recent Pat Drug Deliv Formul 2007; 1(1): 23-36.
235. Prausnitz MR. A practical assessment of transdermal drug delivery by skin electrporation. Adv Drug Deliv Rev 1999; 35: 61-76.
236. Mathur V, Satrawala Y, Rajput MS. Physical and chemical penetration enhancers in transdermal drug delivery system. Asian J Pharm 2010; 4: 173-83.
237. Mitragotri S, Blankschtcin D, Langer R. Ultrasound mediated transdermal protein delivery. Science 1995; 269: 850-3.
238. Murthy SN. Magnetophoresis: an approach to enhance transdermal drug diffusion, Pharmazie 1999; 54: 377-9.
239. Dhamecha D, Rathi AA, et al. Drug vehicle based approaches of penetration enhancement. Int J Pharmacy Pharm Sci 2009; 1: 24-46 INInt.
240. Law S, Huang K, Chiang C. Acyclovir-containing liposomes for potential ocular delivery: corneal penetration and absorption. J Control Release 2000; 63: 135-40.
241. Frederic B, Skiba Malika L, Skiba M. Percutaneous absorption of metopimazine and effect of cyclodextrins. Drug Dev Ind Pharm 2008; 34(5): 478-84.
242. Touitou E, Dayan N, Bergeison L, Levi-Schaffer F, Piliponsky A. Novel lipid vesicular system for enhanced delivery. J Liposomes Res 1998; 8: 112-4.
243. Cevc G, Schatzlein A, Richardsen H. Ultradeformable lipid vesicles can penetrate the skin and other semipermeable barriers unfragmented. Evidence from double label CLSM experiments and direct size measurements. Biochem Biophys Acta 2002; 1564: 21-30.
244. Abdelbary G, El-Gendy N. Niosome-encapsulated gentamicin for ophthalmic controlled delivery. AAPS Pharm Sci Tech 2008; 9(3), 740-7.
245. Moldovan M, Leucuta SE, Bakri A. Preparation and characterization of microemulsions with hydrocortisone acetate. Farmacia 2006; 54: 23-34.
246. Moldovan M, Leucuta SE, Bakri A. Increase of the cutaneous bioavailability of hydrocortisone acetate using a microemulsion vehicle. Farmacia 2006; 54: 35-44.
247. Muller RH, Radtke M, Wissing SA. Solid lipid nanoparticles and nanostructured lipid carriers in cosmetic and dermatologic preparations. Adv Drug Deliv Rev 2002; 54: 77-98.
248. Keleb E, Sharma RK, Mosa EB, Zaljahwi A. Transdermal drug delivery system design and evaluation. Int J Adv Pharm Sci 2010; 1: 201-11.
249. Desai A, Lee M. Gibaldí's Drug delivery systems in pharmaceutial care. Americal Society of Health System Pharmacists Inc. 2007.
250. Bari HA. Prolonged release parenteral drug delivery system-an overview. Int J Pharm Sci Rev Res 2010; 3: 1-11.
251. Robinson JR, Lee VHL. Controlled drug delivery fundamental and application. Marcel Dekker Inc: New York 1987.
252. Remington The Science and Practice of Pharmacy Twenty First Edition, Lippincott: Philadelphia 2000.
253. Banker GS, Rhodes CT. Modern Pharmaceutics, Drugs and Pharmaceutical Sciences 121: M. Dekker, Inc., 2002.
254. Patil SB, Sawant K K. Mucoadhesive microspheres: a promising tool in drug delivery. Curr Drug Deliv 2008; 5: 312-8.
255. Sinha VR, Trehan A. Biodegradable microspheres for parenteral delivery. Crit Rev Ther Drug Carrier Syst. 2005; 22: 535-602.
256. Leucua SE, Ponchel G, Duchene D. Dynamic swelling behaviour of gelatin/poly (acrylic acid) bioadhesive microspheres loaded with oxprenolol. J Microencapsulation 1997; 14: 501-10.
257. Leucua SE, Ponchel G, Duchene D. Oxprenolol release from bioadhesive gelatin/poly (acrylic acid) bioadhesive microspheres. J. Microencapsulation 1997; 14: 511-22.
258. Wissing S A, Kayser O, Muller R H. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev 2004; 56: 1257-72.
259. Muhlen A, Schwartz C, Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery--drug release and release mechanism. Eur J Pharm Biopharm 1998; 45(2): 149-55.
260. Zamboni WC. Liposomal, nanoparticle and conjugated formulation of anticancer agents. Clin Cancer Res 2005; 11: 8230-34.
261. Mamot C, Drummond D C, Hong K, Kirlotin DB, Park JW. Liposome based approaches to overcome anticancer drug resistance. Drug Resist Update 2003; 6: 271-9.
262. Patel R., Patel KP. Advances in novel parentral drug delivery systems. Asian Journal of Pharmaceutics 2010; 4: 193-9.
263. Packhaeuser B, Schnieders J, Oster C G, Kissel T. In situ forming parenteral drug delivery systems: an overview. Eur J Pharm Biopharm 2004; 58: 445-55.
264. Moreau M, Abdellaoui KS, Schneider, Boisramc B, Gurny R. Controlled delivery of metoclopramide using an injectable semisolid poly(ortho ester) for veterinary application. Int J Pharm 2002; 248: 31-7.
265. Dunn R. The Atrigel Drug Delivery System. In: Drugs and the Pharmaceutical Sciences. New York, Dekker Series; 2003, 647-55.
266. Gentner G. Biodegradable block copolymers for delivery of proteins and water-insoluble drugs. J Control Release 2001; 72: 203-15.
267. Murdan S. Organogels in drug delivery. Expert Opin Drug Deliv 2005; 2: 489-505.
268. Anda V, Leroux JC. Organogels and their use in drug delivery-A review. J Contr Release 2007; 125: 179-92.
269. Dash AK, Cudworth GK. Therapeutic applications of implantable drug delivery systems. J Pharmacol Toxicol Meth 1998; 40: 1-12.
270. www.sai-infusion.com/Infusion-Pumps/Alzet-Osmotic-Pump.html.
271. Stevenson CL, Theeuwes F, Wright J C. Osmotic implantable delivery systems. In: Wise D., Ed., Handbook of Pharmaceutical Controlled Release Technology. Marcel Dekker: New York 2000; pp 225-253.
272. Peery JR, Dionne KE, Eckenhoff JB, Landrau FA, Lautenbach SD, Magruder JA, Wright JC. Sustained delivery of an active agent using an implantable system. 1999, US Patent No. 5,985,305.
273. Wright JC, Johnson RM, Yum SI. DUROS® Osmotic Pharmaceutical Systems for Parenteral & Site-Directed Therapy. Drug Dev Deliv 2003; 3: (1) 1-5.
274. Fowler J E, Flanagan M, Gleason DM, Klimberg IW, Gottesman JE, Sharifi R. Evaluation of an implant that delivers leuprolide for one year for the palliative treatment of prostate cancer. Urology 2000; 55: 639-642.
275. Blackshear PJ, Rohde TD. Implantable infusion pumps for drug delivery in man: theoretical and practical considerations. Horiz Biochem Biophys 1989; 9: 293-309.
276. Astra Zeneca. Zoladex, 3.6 mg (goserelin acetate implant) prescribing information. Wilmington 2001.
277. Qiu Y, Park K. Environment sensitive hydrogels for drug delivery. Adv Drug Deliv Rev 2001; 53: 321-39.
278. You JO, Almeda D, Ye GJK, Auguste DT. Bioresponsive matrices in drug delivery. J Biol Eng 2010; 4: 15-9.
279. Gonda I, Byron PR. Perspectives on the biopharmacy of inhalation aerosols: Drug Dev Ind Pharm 1978; 4: 243-51.
280. Hickey AJ. Inhalation aerosols, M. Dekker Inc.: New York 1996.
281. Sanders PA. Aerosol packaging of pharmaceuticals. In: Modern Pharmaceutics, Banker G S, Rhodes CT, Eds., M. Dekker Inc.: New York 1979.
282. Shaikh S, Nazim S, Shaikh A, et al. Recent trends in applications of pulmonary drug delivery: a review. Int J Pharm Res Dev-online 2011; 2: 171-180.
283. Cipolla D. et al. Delivery of biologics to the lung. In: Hansel TT, Barnes P J, Eds., New drugs for asthma and COPD, Prog Respir Res Basel, Karger 2010, vol.39, pp 1-14.
284. Adjei LA, Gupta PK. Inhalation delivery of therapeutic peptides and proteins, M. Dekker Inc.: New York 1997.
285. Noymer PD, Schuster J, Holst P. Developing a next-generation pulmonary drug delivery system. Drug Dev Deliv 2004; 4 (8): 1-4.
286. Schuster J, Farr S. The AERx® pulmonary drug delivery system. In: Rathbone M, Hadgraft J, Roberts M, Eds. Modified-Release Drug Delivery Technology. Marcel Dekker Inc.: New York 2002; pp 825-34.
287. Thipphawong J, Otulana B, Clauson P, Okikawa J, Farr S. Pulmonary insulin administration using the AERx® insulin diabetes system. Diabetes Technol Therapeut 2002; 4: 499-504.
288. Schreier H, Gonzalez-Rothi RJ, Stecenko AA. Pulmonary delivery of liposomes. J Contr Release 1993; 24: 209-23.
289. Lawrence MJ, Rees GD. Microemulsion-based media as novel drug delivery systems. Adv Drug Del Rev 2000; 45: 89-121.
290. Sinha VR, Trehan A. Biodegradable microspheres for parenteral delivery. Crit Rev Ther Drug Carrier Syst 2005; 22(6): 535-602.
291. Morimoto K, Katsumata H, Yabuta T, et al. Gelatin microspheres as a pulmonary delivery system: evaluation of salmon calcitonin absorption. J Pharm Pharmacol 2000; 52: 611-7.
292. Smola M, Vandamme T, Sokolowski A. Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases. Int J Nanomedicine 2008; 3(1): 1-19.
293. Kawashima Y, Yamamoto H, Takeuchi H, et al. Pulmonary delivery of insulin with nebulized DL-lactide/glycolide copolymer (PLGA) nanospheres to prolong hypoglycemic effect. J Control Rel 1999; 62: 279-87.
294. Duchene D, Touchard F, Peppas NA. Pharmaceutical and medical aspects of bioadhesive system for drug administration. Drug Dev Ind Pharm 1998; 14: 283-381.
295. Bravo-Osuna I, Vauthier C, Farabollini A, Palmieri GF, Ponchel G. Mucoadhesion mechanism of chitosan and thiolated chitosanpoly(isobutyl cyanoacrylate) core-shell nanoparticles. Biomaterials 2007; 28(13): 2233-43.
296. Boddupalli BM, Mohammed ZNK, Nath RA, Banji D. Mucoadhesive drug delivery system: An overview. J Advanced Pharm Technol Res 2010; 1: pp 381-7.
297. Faivre V. Aspects theoriques de la bioadhesion. In: Falson-Rieg V, Faivre V, Pirot F., Eds. Nonvelles formes medicamenteuses, Editions Medicales Internationales, Editions TEC and DOC, Cachan. 2004; pp 1-24.
298. Huang Y, Leobandung W, Foss A, Peppas NA. Molecular aspects of muco-and bioadhesion: tethered structures and site-specific surfaces. J Contr Release 2000; 65: 63-71.
299. Mathiowitz E, Chickering DE, Lehr CM. Bioadhesive drug delivery systems: fundamentals, novel approaches, and development. Marcel Dekker 1999.
300. Llabot J M, Salman H, Millotti G, Bernkop-Schnurch A, Allemandi D, Irache JM. Bioadhesive properties of poly(anhydride) nanoparticles coated with different molecular weights chitosan. J Microencapsulation 2011; DOI: 10.3109/02652048.2011.576787.
301. Labarre D, Ponchel G, Vauthier C. Biomedical and Pharmaceutical Excipients, ULA Pharmacy Series, Pharmaceutical Press 2011.
302. Carvalho FC, Bruschi ML, Evangelista RC, Gremiao MPD. Mucoadhesive drug delivery systems. Braz J Pharm Sci 2010; 46: 1-17.
303. Agueros M, Areses P, Campanero MA, Salman H, Quincoces G, Penuelas I, Irache JM: Bioadhesive properties and biodistribution of cyclodextrin-poly(anhydride) nanoparticles. Eur J Pharm Sci 2009; 37: 231-40.
304. Mathiowitz E, Chickering D E, Lehr CM. Bioadhesive drug delivery systems: Fundamentals, novel approaches and developments. M. Dekker: New York 1999; pp 76-102.
305. Lenaerts V, Gurny R. Bioadhesive drug delivery systems, CRC Press 1990.
306. Patel AR, Patel DA, Chaudhry SV. Mucoadhesive buccal drug delivery system. Int J Pharm & Life Sci (IJPLS) 2011; 2: 848-56.
307. Cid YP, Pedrazzi V, Sousa VP, Pierre MBR. In vitro characterization of chitosan gels for buccal delivery of celecoxib: influence of a penetration enhancer. AAPS Pharm Sci Tech 2012; 13: 101-11.
308. Dinte E, Tomuta I, Leucuta SE. Influence of the formulation on the release of metronidazole from bioadhesive tablets based on Carbopol 940 and hydroxypropylmethylcellulose. Farmacia 2005; 53: 74-9.
309. Verma N, Chattopadhyay P. Polymeric platform for mucoadhesive buccal drug delivery system: a review. Int J Curr Pharm Res 2011; 3: 3-8.
310. Biswajit B, Kevin G, Thimmasetty J. Formulation and evaluation of pimozide buccal mucoadhesive patches. Int J Pharm Sci Nanotechnol 2010; 2: pp 32-41.
311. Illum L. Microspheres as a potential controlled release nasal drug delivery system. In: Delivery Systems for Peptide and Drugs, Davis SS, Illum L, Tomlinson E, Eds., Plenum Press: New York 1986; pp, 205-10.
312. Illum L, Farraj NF, Critchley H, Davis SS.: Nasal administration of gentamicin using a novel microsphere delivery system. Int J Pharm 1988; 46: 261-5.
313. Farraj NF, Johansen BR, Davis SS, Illum L. Nasal administration of of insulin using bioadhesive microspheres as a delivery system, J Contr Release 1990; 13: 253-61.
314. Turker S, Onur E, Ozer Y. Nasal route and drug delivery systems. Pharmacy World Sci; 26: 137-42.
315. Vasir JK, Tambwekar K, Garg S. Mucoadhesive tablets as a controlled drug delivery system. Int J Pharm 2003; 255: 13-32.
316. Preda M, Leucuta SE. Oxprenolol-loaded bioadhesive microspheres: preparation and in vitro/in vivo characterization. J Microencapsulation 2003; 20: 777-90.
317. Porfire AS, Zabaleta V, Gamazo C, Leucua SE, Irache JM. Influence of dextran on the bioadhesive properties of poly(anhydride) nanoparticles. Int J Pharm 2010; 390: 37-44.
318. Friend D R. Advances in vaginal drug delivery. Drug Deliv Transl Res 2011; 1: 183-4.
319. Acarturk F. Mucoadhesive vaginal drug delivery systems. Recent Pat Drug Deliv Formul 2009; 3: 193-205.
320. Pereira RRA, Bruschi ML. Vaginal mucoadhesive drug delivery systems. Drug Dev Ind Pharm 2011; 1: 1-10.
321. Choudhury A, Das S, Kar M. A review on novelty and potentiality of vaginal drug delivery. International Journal of PharmTech Research 2011; 3 (2): 1033-44.
322. Laszlo E, Vlase L, Leucuta SE. Kinetic modeling of drug release from experimental pharmaceutical gels containing clotrimazole. Farmacia 2006; 54: 25-32.
323. Aka-Any-Grah A, Bouchemal K, Koffi A, Agnely F, Zhang M, Djabourov M, Ponchel G. Formulation of mucoadhesive vaginal hydrogels insensitive to dilution with vaginal fluids. Eur J Pharm Biopharm 2010; 76(2): 296-303.
324. Shilpa K, Poddar SS. Design of mucoadhesive vaginal metronidazole films. Acta Pharm Sciencia 2010; 52: 181-9.
325. Benagiano G, Gabelnick H, Farris M. Contraceptive devices: intravaginal and intrauterine delivery systems. Expert Rev Med Devices. 2008; 5(5): 639-54.
326. Wilson CG, Washington N. Physiological Pharmaceutics Barriers to Drug Absorption. CRC Press 2000 faculty. ksu. edu. sa/72820/ Documents/Lecture. ppt.
327. Mazza D. Women's Health in General Practice. Churchill Livingstone 2011; 2nd Edition.
328. World Health Organization. The intrauterine device (IUD)-worth singing about. Progress in Reproductive Health Research 2002; 60: 1-8.
329. www.authorstream.com/Presentation/gurpreet99-394557-vaginaldrug-delivery.
330. Ranade VV, Hollinger MA. Drug Delivery Systems, CRC Press: 2004, 2nd Ed.
331. Progestasert package insert (Intrauterine progesterone contraceptive system, Alza-US), Rev 5/93, Rec 5/95.
332. Wildemeersch D, Dhont M, Weyers S, Temmerman M. Miniature low dose intrauterine drug delivery systems. Annals of the New York Academy of Sciences 2003; 997: 174-84.
333. Hillery AM, Lloyd AW, Swarbrick J. Drug delivery and targeting: for pharmacists and pharmaceutical sciences, Francis &Taylor: London 2001.
334. Petrak K. Essential properties of drug targeting delivery systems. Drug Discov. Today (DDT) 2005, 10: 1667-73.
335. Lee VHL. Advanced drug delivery in the post-genomic era. Editorial, Adv Drug Deliv Rev 2009; 61: 1389-90.
336. Molema G, Meijer DKF. Drug targeting: organ-specific strategies, Wiley 2001.
337. Ranade VV, Cannon JB. Drug Delivery Systems. CRC Press: Boca Raton 2011.
338. Metzger Filho O, Moulin C, Awada A. Molecular targeted therapy in prevalent tumors: learning from the past and future perspectives. Curr Clin Pharmacol 2010; 5: 166-177.
339. Sood A, Panchagnula R. Peroral route: an opportunity for protein and peptide drug delivery. Chem Rev 2001; 101: 3275-303.
340. Fasano A. Innovative strategies for the oral delivery of drugs and peptides. Trends Biotechnol 1998; 16: 152-7.
341. Swaan P W. Recent advances in intestinal macromolecular drug delivery via receptor-mediated transport pathways. Pharm Res 1998; 15: 826-34.
342. Kostarelos K. Rational design and engineering of delivery systems for therapeutics: biomedical exercises in colloid and surface science. Adv Colloid Interface Sci 2003; 106: 147-68.
343. Ferrari M. Nanovector therapeutics. Curr Opin Chem Biol 2005; 9: pp 343-6.
344. Moghimi S M, Hunter A C, Murray J K. Nanomedicine: current status and future prospects. Adv Drug Deliv Rev 2005; 17: 61-73.
345. Vasir JK, Reddy MK, Labhasetwar VD. Nanosystems in drug targeting: opportunities and challenges. Current Nanoscience 2005; 1: 47-64.
346. Schweitzer M, Flory E. Somatic gene therapy-advanced biotechnology products in clinical development. In: Kayser O, Muller R H E, Eds. Pharmaceutical Biotechnology, Drug Discovery and Clinical Applications. Wiley-VCH Verlag GmbH & Co.: Weinheim 2004.
347. Prokop A. Intracellular delivery. Fundamentals and applications. Springer 2011.
348. Kumar C. Tissue, cell and organ engineering, Willey VCF 2006.
349. Schwyzer R. How do peptides interact with lipid membranes and how does this affect their biological activity? Braz J Med Biol Res 1992; 25: 1077-89.
350. Rajendran L, Knolker HJ., Simons K. Subcellular targeting strategies for drug design and delivery. Nature Reviews Drug Discovery.2010; 9: 29-42.
351. Desai M, Pattani A. Intracellular drug delivery systems: A new paradigm. Express Pharma 2006. www.expresspharmaonline.com/ 20060815/research03.shtm.
352. Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev 2003; 55: 329-47.
353. Mellman I. Endocytosis and molecular sorting. Annu Rev Cell Dev Biol 1996; 12: 575-625.
354. Cho K, Wang X, Nie S, Chen Z, Shin DM. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 2008; 14: 1310-6.
355. Xiao Z., Levy-Nissenbaum E., Alexis F. Engineering of Targeted Nanoparticles for Cancer Therapy Using Internalizing Aptamers Isolated by Cell-Uptake Selection. ACS Nano, 2012, 6: (1), 696-704.
356. Leucuta SE. Nanotechnology for delivery of drugs and biomedical applications. Curr Clin Pharmacol 2010; 5: 257-80.
357. Vauthier C, Labarre D, Ponchel D. Design aspects of poly(alkylcyanoacrylate) nanoparticles for drug delivery. J Drug Targeting 2007; 15(10): 641-63.
358. Lahiani Skiba M, Bounoure F, Shawky Tous S, Arnaud P, Skiba M. Optimization of entrapment of metronidazole in amphiphilic beta-cyclodextrin nanospheres. J Pharm Biomed Anal 2006; 41: 1017-21.
359. Sonvico F, Dubernet C, Colombo P, Couvreur P. Metallic colloid nanotechnology, applications in diagnosis and therapeutics. Curr Pharm Design 2005; 11: 2095-105.
360. Marin GH, Mansilla E, Mezzaroba N, et al. Exploratory study on the effects of biodegradable nanoparticles with drugs on malignant b cells and on a human/mouse model of burkitt lymphoma. Curr Clin Pharmacol 2010; 5: 246-50.
361. Gasparyan VK. Gold and silver nanoparticles in bioassay, cell visualization and therapy. Curr Clin Pharmacol 2009; 4: 159-63.
362. Valotassiou V, Wozniak G, Sifakis N, et al. Radiopharmaceuticals in neurological and psychiatric disorders. Curr Clin Pharmacol 2008; 3: 99-107.
363. Lallana E, Fernandez-Trillo F, Sousa-Herves A et al. Click chemistry with polymers, dendrimers, and hydrogels for drug delivery. Pharmaceutical Research 2012; 29: 902-921.
364. Hoffman A. www.uweb.engr.washington.edu/./HoffmannPDFs/3-InjectableDDS. Routes of drug delivery.
365. Amiji MA. Nanotechnology-Improving targeted delivery. Drug Delivery 2007; pp 52-6.
366. Amiji MA. Nanotechnology for cancer therapy. CRC Press, Taylor and Francis Group 2007.
367. Allemann GE, Fessi H, Doelker E. Polymeric nanoparticles for oral delivery of drugs and vaccines: a critical evaluation of in vivo studies. Crit Rev Ther Drug Carrier Syst 2005; 22: 419-64.
368. Jain RK. Delivery of molecular and cellular medicine to solid tumors. Adv Drug Deliv Rev 2001; 46: 149-68.
369. Torchilin VP. Passive and active drug targeting: drug delivery to tumors as an example. Handb Exp Pharmacol 2010; (197): 3-53.
370. Marcato PD, Duran N. New aspects of nanopharmaceutical delivery systems. J Nanosci Nanotech 2008; 8: 1-14.
371. Bawa R. Nanoparticle based therapeutics in humans: a survey. Nanotechnology Law and Business 2008; 5: (2)135-55.
372. Torchilin VP. Multifunctional nanocarriers. Adv Drug Deliv Rev 2006; 58: 1532-55.
373. Danhier F, Feron O, Preat V. To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Contr Release 2010; 148: 135-46.
374. Chamuleau MED, van de Loosdrecht AA, Huijgens PC. Monoclonal antibody therapy in haematological malignancies. Curr Clin Pharmacol 2010; 5: 148-159.
375. Torchilin VP. Recent approaches to intracellular delivery of dugs and DNA and organelle targeting. Annu Rev Biomed Eng 2006; 8: 343-75.
376. Zaki NM, Tirelli N. Gateways for the intracellular access of nanocarriers: a review of receptor-mediated endocytosis mechanisms and of strategies in receptor targeting. Expert Opin Drug Deliv 2010; 7: 895-913.
377. Manjunath N, Dykxhoorn DM. Advances in synthetic siRNA delivery. Discovery Medicine 2010; 9: (48) 418-30.
378. Lambert G, Fattal E, Couvreur P. Nanoparticulate systems for the delivery of antisense oligonucleotides. Adv Drug Deliv Rev 2001; 47: 99-112.
379. Hohjoh H. RNA interference (RNAi) induction with various types of synthetic oligonucleotide duplexes in cultured human cells. FEBS Lett 2002; 521: 195-9.
380. Saonere JA. Antisense therapy, a magic bullet for the treatment of various diseases: present and future prospects. J Med Genet Genom 2011; 3: 77-83.
381. Boeckle S, Wagner E. Optimizing targeted gene delivery: chemical modification of viral vectors and synthesis of artificial virus vector systems. AAPS Journal 2006; 8: E731-E742.
382. Al-Dosari M, Gao X. Nonviral gene delivery: principle, limitations and recent progress. AAPS Journal 2009; 11: 671-80.
383. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000; 288: 669-72.
384. Hacein-Bey-Abina S, Fischer A, Cavazzana-Calvo M. Gene therapy of X-linked severe combined immunodeficiency. Int J Hematol 2002; 76: 295-98.
385. Hacein-Bey-Abina S, von Kalle C, Schmidt M, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003; 348: 255-6.
386. Li F, Huang L. Development of non-viral vectors for systemic gene delivery. J Control Release 2002; 78: 259-66.
387. Felgner PL, Ringold GM. Cationic liposome-mediated transfection. Nature 1989; 337: 387-8.
388. Niidome T, Huang L. Gene therapy progress and prospects: nonviral vectors. Gene Ther 2002; 9: 1647-52.
389. Felgner JH, Kumar R, Sridhar CN, et al. Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations. J Biol Chem 1994; 269: 2550-61.
390. Gershon H, Ghirlando R, Guttman SB, Minsky A. Mode of formation and structural features of DNA-cationic liposome complexes used for transfection. Biochemistry 1993; 32: 7143-51.
391. Felgner PL, Barenholz Y, Behr JP, et al. Nomenclature for synthetic gene delivery systems. Hum Gene Ther 1997; 8: 511-2.
392. Branden LJ, Smith CIE. Bioplex technology: novel synthetic gene delivery system based on peptides anchored to nucleic acids. Methods Enzymol 2002; 346: 106-24.
393. Lundin KE, Simonson OE, Moreno PMD, et al. Nanotechnology approaches for gene transfer. Genetica 2009; 137: 47-56.
394. Simonson OE, Svahn MG, Tornquist E, Lundin KE, Smith CIE. Bioplex technology: novel synthetic gene delivery pharmaceutical based on peptides anchored to nucleic acids. Curr Pharm Des 2005; 11: 3671-80.
395. Lundin KE, Hassan M, Moreno PM, et al. Increased stability and specificity through combined hybridization of peptide nucleic acid (PNA) and locked nucleic acid (LNA) to supercoiled plasmids for PNA-anchored "Bioplex" formation. Biomol Eng 2005; 22: 185-92.
396. Oprea I, Simonson OE, Moreno PMD, Viola JR. Lundin KE, Smith Edvard CIE. Temperature assisted cyclic hybridization (TACH): an improved method for supercoiled DNA hybridization. Mol Biol 2010; 45: 171-9.